Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhongqiu Pang

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biochemical and Biophysical Research Communications|June 4, 2025
CDKL3, a versatile kinase with increasing recognitionLanjing Ma, Haijiao Zhang, Zhongqiu Pang, et al.
FEBS Open Bio|June 9, 2017
Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cellsSiwei Liu, Bilin Liang, Huiting Jia, et al.
Advanced Healthcare Materials|July 6, 2023
Anti-Pan-Rspo Chimeric Protein-Conjugated Albumin Nanoparticle Provides Promising Opportunities in Cancer Targeted TherapyShaoqin Zheng, Xi Zhang, Zhongqiu Pang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 17, 2022
Aberrant Cholesterol Metabolism and Wnt/β-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer GrowthShaoqin Zheng, Jiahui Lin, Zhongqiu Pang, et al.
Hepatology (Baltimore, Md.)|December 11, 2024
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylationZhongqiu Pang, Hui Zhang, Shaoqin Zheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2025
Clear cell renal carcinoma essentially requires CDKL3 for oncogenesisLanjing Ma, Zhongqiu Pang, Haijiao Zhang, et al.
The Journal of Clinical Investigation|July 4, 2024
CDKL3 is a targetable regulator of cell cycle progression in cancersHaijiao Zhang, Jiahui Lin, Shaoqin Zheng, et al.
Cell Chemical Biology|August 23, 2023
USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potentialYinuo Wang, Aihua Mao, Jingwei Liu, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biochemical and Biophysical Research Communications|June 4, 2025
CDKL3, a versatile kinase with increasing recognitionLanjing Ma, Haijiao Zhang, Zhongqiu Pang, et al.
FEBS Open Bio|June 9, 2017
Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cellsSiwei Liu, Bilin Liang, Huiting Jia, et al.
Advanced Healthcare Materials|July 6, 2023
Anti-Pan-Rspo Chimeric Protein-Conjugated Albumin Nanoparticle Provides Promising Opportunities in Cancer Targeted TherapyShaoqin Zheng, Xi Zhang, Zhongqiu Pang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|August 17, 2022
Aberrant Cholesterol Metabolism and Wnt/β-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer GrowthShaoqin Zheng, Jiahui Lin, Zhongqiu Pang, et al.
Hepatology (Baltimore, Md.)|December 11, 2024
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylationZhongqiu Pang, Hui Zhang, Shaoqin Zheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2025
Clear cell renal carcinoma essentially requires CDKL3 for oncogenesisLanjing Ma, Zhongqiu Pang, Haijiao Zhang, et al.
The Journal of Clinical Investigation|July 4, 2024
CDKL3 is a targetable regulator of cell cycle progression in cancersHaijiao Zhang, Jiahui Lin, Shaoqin Zheng, et al.
Cell Chemical Biology|August 23, 2023
USP10 strikes down β-catenin by dual-wielding deubiquitinase activity and phase separation potentialYinuo Wang, Aihua Mao, Jingwei Liu, et al.
Pageof 1